U. Brennscheidt
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Immunotherapy and Immune Responses, Colorectal Cancer Treatments and Studies, Lung Cancer Diagnosis and Treatment, CAR-T cell therapy research
Most-Cited Works
- → Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer (NSCLC)(2004)300 cited
- → Exploratory analyses EGFR, kRAS mutations and other molecular markers in tumors of NSCLC patients (pts) treated with chemotherapy +/- erlotinib (TALENT)(2005)41 cited
- → Induction of tumor-specific cytotoxic T lymphocytes by immunization with autologous tumor cells and interleukin-2 gene transfected fibroblasts(1997)38 cited
- → Palmar fibromatosis (Dupuytren's contracture)(1984)37 cited
- → A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients(2007)36 cited
- Mechanisms of p53 alteration in acute leukemias.(1994)
- raf oncogenes in carcinogenesis.(1990)
- → Phase 1b Dose Escalation Study of Erlotinib in Combination with Infusional 5-Fluorouracil, Leucovorin, and Oxaliplatin in Patients with Advanced Solid Tumors(2007)24 cited
- → Molecular Organization of the Human Raf-1 Promoter Region(1990)24 cited
- Raf-1 is a necessary component of the mitogenic response of the human megakaryoblastic leukemia cell line MO7 to human stem cell factor, granulocyte-macrophage colony-stimulating factor, interleukin 3, and interleukin 9.(1994)